POS1233 DIFFICULTIES AND MENTAL IMPACT OF THE SARS-CoV- 2 PANDEMIC IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A NATIONWIDE PATIENT ASSOCIATION STUDY

Background The COVID-19 pandemic has taken a toll on the mental health of general population. Patients with systemic lupus erythematosus (SLE) were particularly exposed due to many uncertainties linked virus and their immunosuppression as well difficulties access medical care treatment (eg, hydroxychloroquine) during early pandemic. Objectives To evaluate encountered by SLE patients pandemic, impact patient health. Methods We conducted nationwide survey including from France metropolitan overseas territories, recruited treating specialist or through association (AFL+). was administered online in paper form between November 2020 April 2021, included questions aiming at evaluating (March August 2020). evaluated using Hospital Anxiety depression scale (HADS) post-traumatic stress disorder (PTSD) Checklist for DSM-5 (PCL-5). Results 536 (91.9% women) mean age 50 (±14.1) years responded survey. main reported issues (n = 136, 25.4%) obtain hydroxychloroquine 98/389, 25.2%), loss employment 85/349, 24.4%) financial 75/536, 11%). Hydroxychloroquine shortage responsible obtaining drug 25.2% (98/389) HCQ-treated patients, 57 had interrupt HCQ median 7 days (IQR: 3-17). In 342 complete assessment, 161 (47.2%) screened positive anxiety, 141 (41.2%) depressive syndrome 128 (38.7%) PTSD. Multivariate analysis showed that female sex (OR=4.29 [95%CI: 1.39-13.24]), (OR=2.57 [1.27-5.22]), (OR=2.15 [1.26-3.69]), (OR=1.90 [1.06-3.40]) independently associated screening Conclusion resulted severe burden along high psychological distress. Better understanding these will allow better prevention times crisis. Table 1. Factors development Odds ratio (CI95%) multivariate logistic regression are shown. Patient pandemic-associated factors (95%CI) anxiety PTSD Female 2.25 (0.97-5.25), p 0.058 ns 4.29 (1.39-13.24 ) 0.01 Financial 2.59 (1.31-5.11 0.006 2.57 (1.27-5.22 0.009 Difficulties 1.70 (0.97-2.98 0.065 1.90 (1.06-3.40 0.03 1.94 (1.15 3.25 0.012 (1.53-4.33 < 0.0001 2.15 (1.26-3.69 0.005 Acknowledgements Antonin Folliasson his help. Disclosure Interests Marc SCHERLINGER: None declared, naimah zein: Jacques-Eric Gottenberg: Marianne Riviere: Jean François Kleinmann: Sibilia: Laurent Arnaud Speakers bureau: Alexion, Amgen, Astra-Zeneca, Abbvie, Biogen, BMS, Boehringer-Ingelheim, Cêmka, Kezar, GSK, Grifols, Janssen, LFB, Lilly, Menarini France, Medac, Novartis, Oséus, Pfizer, Roche-Chugaï, Sêmeia, UCB., Consultant of: consultant UCB.